Cargando…

Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer

BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and its incidence seriously affects human health. The purpose of this study was to evaluate the efficacy and safety of anlotinib in patients with advanced NSCLC. METHODS: A retrospective study was conducted on 150...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Yuejiao, Wei, Qiang, Lu, You, Tang, Xiuliang, Wang, Zhongqiu, Chen, Lingxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656407/
https://www.ncbi.nlm.nih.gov/pubmed/33209434
http://dx.doi.org/10.21037/jtd-20-2855
_version_ 1783608376801886208
author Zhong, Yuejiao
Wei, Qiang
Lu, You
Tang, Xiuliang
Wang, Zhongqiu
Chen, Lingxiang
author_facet Zhong, Yuejiao
Wei, Qiang
Lu, You
Tang, Xiuliang
Wang, Zhongqiu
Chen, Lingxiang
author_sort Zhong, Yuejiao
collection PubMed
description BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and its incidence seriously affects human health. The purpose of this study was to evaluate the efficacy and safety of anlotinib in patients with advanced NSCLC. METHODS: A retrospective study was conducted on 150 patients with advanced NSCLC who were treated with anlotinib and discontinued treatment after disease progression or intolerance due to adverse events. Progression-free survival (PFS) of advanced NSCLC patients served as an endpoint. Kaplan-Meier survival curves were applied to evaluate the short-term efficacy of anlotinib treatment in advanced NSCLC patients. RESULTS: The median PFS of the whole 150-patient cohort was 5.0 months in (95% CI: 4.00–5.95), 5.0 months (95% CI: 3.0–6.00) in 90 patients with adenocarcinoma, and 4.5 months (95% CI: 4.00–7.00) in 60 patients with squamous cell carcinoma (P=0.676). The PFS was 6.5 months (95% CI: 4.00–8.80) and 4.5 months (95% CI: 4.00–5.60) in the first-/second-line and ≥ third-line patients, respectively (P=0.315). Following the Eastern Cooperative Oncology Group performance status (ECOG PS) score, the median PFS of 95 patients with a PS score 0–1 was 5.5 months (95% CI: 4.50–6.50), and the median PFS of 55 patients with a PS score ntswas 4.0 months (95% CI: 3.00–5.00) (P=0.221). For the 49 patients in the combination group the median PFS was 7.0 months (95% CI: 4.00–9.00), while that of the 101 patients in the anlotinib-alone group was 4.0 months in (95% CI: 2.80–5.50) (P=0.010). In a separate analysis of the combination group, the median PFS of anlotinib combined with chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), and immunotherapy was 5.5 months (95% CI: 4.00–9.00), 12.0 months (95% CI: 6.00–12.00), and 6.5 months (95% CI: 4.00–9.80), respectively (P=0.036). CONCLUSIONS: Anlotinib exhibits good tolerance and performance in prolonging the PFS of patients and has considerable potential as a treatment for advanced NSCLC.
format Online
Article
Text
id pubmed-7656407
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-76564072020-11-17 Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer Zhong, Yuejiao Wei, Qiang Lu, You Tang, Xiuliang Wang, Zhongqiu Chen, Lingxiang J Thorac Dis Original Article BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and its incidence seriously affects human health. The purpose of this study was to evaluate the efficacy and safety of anlotinib in patients with advanced NSCLC. METHODS: A retrospective study was conducted on 150 patients with advanced NSCLC who were treated with anlotinib and discontinued treatment after disease progression or intolerance due to adverse events. Progression-free survival (PFS) of advanced NSCLC patients served as an endpoint. Kaplan-Meier survival curves were applied to evaluate the short-term efficacy of anlotinib treatment in advanced NSCLC patients. RESULTS: The median PFS of the whole 150-patient cohort was 5.0 months in (95% CI: 4.00–5.95), 5.0 months (95% CI: 3.0–6.00) in 90 patients with adenocarcinoma, and 4.5 months (95% CI: 4.00–7.00) in 60 patients with squamous cell carcinoma (P=0.676). The PFS was 6.5 months (95% CI: 4.00–8.80) and 4.5 months (95% CI: 4.00–5.60) in the first-/second-line and ≥ third-line patients, respectively (P=0.315). Following the Eastern Cooperative Oncology Group performance status (ECOG PS) score, the median PFS of 95 patients with a PS score 0–1 was 5.5 months (95% CI: 4.50–6.50), and the median PFS of 55 patients with a PS score ntswas 4.0 months (95% CI: 3.00–5.00) (P=0.221). For the 49 patients in the combination group the median PFS was 7.0 months (95% CI: 4.00–9.00), while that of the 101 patients in the anlotinib-alone group was 4.0 months in (95% CI: 2.80–5.50) (P=0.010). In a separate analysis of the combination group, the median PFS of anlotinib combined with chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), and immunotherapy was 5.5 months (95% CI: 4.00–9.00), 12.0 months (95% CI: 6.00–12.00), and 6.5 months (95% CI: 4.00–9.80), respectively (P=0.036). CONCLUSIONS: Anlotinib exhibits good tolerance and performance in prolonging the PFS of patients and has considerable potential as a treatment for advanced NSCLC. AME Publishing Company 2020-10 /pmc/articles/PMC7656407/ /pubmed/33209434 http://dx.doi.org/10.21037/jtd-20-2855 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Zhong, Yuejiao
Wei, Qiang
Lu, You
Tang, Xiuliang
Wang, Zhongqiu
Chen, Lingxiang
Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer
title Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer
title_full Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer
title_fullStr Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer
title_full_unstemmed Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer
title_short Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer
title_sort efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656407/
https://www.ncbi.nlm.nih.gov/pubmed/33209434
http://dx.doi.org/10.21037/jtd-20-2855
work_keys_str_mv AT zhongyuejiao efficacyandsafetyofanlotinibinpatientswithadvancednonsmallcelllungcancer
AT weiqiang efficacyandsafetyofanlotinibinpatientswithadvancednonsmallcelllungcancer
AT luyou efficacyandsafetyofanlotinibinpatientswithadvancednonsmallcelllungcancer
AT tangxiuliang efficacyandsafetyofanlotinibinpatientswithadvancednonsmallcelllungcancer
AT wangzhongqiu efficacyandsafetyofanlotinibinpatientswithadvancednonsmallcelllungcancer
AT chenlingxiang efficacyandsafetyofanlotinibinpatientswithadvancednonsmallcelllungcancer